Giordano Botta: VA and Allelica Partner on Clinical Study of PRS and PGx in Cardiovascular Prevention
Giordano Botta, CEO and Co-Founder of Allelica, shared a post on LinkedIn:
“We are proud to partner with the U.S. Department of Veterans Affairs, the largest integrated healthcare system in the United States, on a randomized clinical trial evaluating the impact of polygenic risk score (PRS) and pharmacogenomics (PGx) in routine care.
This comes at a pivotal moment, as the new 2026 ACC/AHA guidelines now include PRS as a risk enhancing factor.
The study will compare standard care with a genomic guided approach.
Patients in the intervention arm will receive the Allelica multi-ancestry PRS for coronary artery disease together with PGx testing for statin response, including SLCO1B1.
The objective is to assess whether integrating genetic risk and drug response can improve statin prescription, adherence, and ultimately cardiovascular outcomes.
We look forward to supporting this clinical trial, designed to generate prospective evidence on the clinical utility of integrating PRS and PGx into cardiovascular prevention, with the potential to inform implementation at scale across large healthcare systems.”
Stay updated with Hemostasis Today.
-
Jun 29, 2026, 06:48Christina Pohlman: Anticoagulants and Bone Health – APS Awareness Month Day 23
-
Jun 29, 2026, 06:33Andreas Calatzis: Can Fibrinolysis Sensitivity Be Claimed Without a Reference Standard
-
Jun 29, 2026, 06:25Aliaa Albadri: When a Hair Wash Leads to a Stroke Workup
-
Jun 29, 2026, 06:22Tehreen Parveen: Historical Milestone in Drug Discovery – The Discovery of Aspirin
-
Jun 29, 2026, 06:16Muhammad Sufyan: Deep Vein Thrombosis – Recognizing the Warning Signs
-
Jun 29, 2026, 05:33Janak Sadhu: Uniting for The Stroke-Free Mehsana Initiative
-
Jun 29, 2026, 05:20Deepti Sachan: A Global Exchange Shaping the Future of Transfusion Medicine at ISBT 2026
-
Jun 29, 2026, 04:50Scott Cameron: ACC/AHA Guidance on Acute Pulmonary Embolism Management
-
Jun 29, 2026, 03:10Aryabhatta Sadhu: ABO and Rh Incompatibility In Stem Cell Transplantation